GHRH (1-44)
The native 44-residue human growth hormone-releasing hormone, isolated from pancreatic tumors in 1982 and named somatorelin for pituitary diagnostic testing abroad, with no FDA-approved product and no active US development of the unmodified peptide.
Also referenced as: Somatorelin, Somatorelin acetate, Somatocrinin, Somatoliberin, GRF(1-44), GHRH(1-44)-NH2, hpGRF-44, GRF
Also appears in: Hormone
Public product evidence No certificate records are bound to a tracked GHRH (1-44) product page A record counts here only when a vendor publishes a certificate against one of its own tracked GHRH (1-44) product pages. Other certificates naming this compound may still exist — search the wider certificate database.This name primarily lives in the research market and should not be read like an approved pharmaceutical product.
Primary research area: GH axis. Also surfaces under Hormone for browsing and discovery.
Where the compound acts, as a browse axis. It is an editorial grouping for discovery, not a claim about labeled indications.
Somatorelin, Somatorelin acetate, Somatocrinin, Somatoliberin, GRF(1-44), GHRH(1-44)-NH2, hpGRF-44, GRF
No FDA label signal · 59 trials · 233 PubMed results
GHRH (1-44) has name-matched human trials with published or reported controlled evidence, but is not FDA-approved. The research is real and ongoing — treat findings as developing rather than settled.
GHRH (1-44) has 7 name-matched clinical trials (highest phase: Phase 2) and 233 PubMed-indexed publications and is not FDA-approved. 3 trials have posted results.
Re-checked nightly against the registries — tracked since 2026-11-17. No band changes yet.
Grades evidence strength, not efficacy or safety. Research-use context; not medical advice. Graded 2026-11-18 from PubMed, ClinicalTrials.gov, ISRCTN, openFDA, Health Canada, and OpenAlex — computed deterministically and refreshed nightly, with a retraction check. How we grade →
What is GHRH (1-44)?
GHRH (1-44) is the native human growth hormone-releasing hormone: a 44-amino-acid peptide with a C-terminal amide, released by hypothalamic neurons into the pituitary portal circulation to drive growth hormone secretion from somatotrophs. It was isolated in 1982 from pancreatic islet tumors in patients with acromegaly. Guillemin’s group reported the full 44-residue sequence, Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu-NH2, and showed that the synthetic replicate had full growth hormone-releasing activity (Guillemin et al., Science, 1982;218(4572):585–587), while Vale’s group characterized a 40-residue form from a second tumor (Rivier et al., Nature, 1982;300(5889):276–278). The hypothalamic peptide, isolated two years later, proved identical to the tumor-derived 44-residue form (Ling et al., Proceedings of the National Academy of Sciences, 1984;81(14):4302–4306). It is cut from a larger precursor encoded by a single-copy gene on chromosome 20 (Mayo et al., Proceedings of the National Academy of Sciences, 1985;82(1):63–67), and the free peptide has the molecular formula C215H358N72O66S and a molecular weight of about 5,040 Da. The international nonproprietary name is somatorelin, the Japanese Accepted Name for the salt is somatorelin acetate, and older literature calls it somatocrinin, somatoliberin, GRF(1-44) or hpGRF-44.
The native hormone is the parent of every GHRH-class drug. Sermorelin is the 1-29 fragment, the shortest segment with full activity; tesamorelin is the complete 1-44 sequence with a trans-3-hexenoyl group on the N-terminal tyrosine; and CJC-1295 and CJC-1295 no DAC are substituted 1-29 analogs. None of these is the same molecule as GHRH (1-44). No native GHRH product has ever been approved in the United States, and the unmodified peptide circulates in the research-peptide market under the bare label “GHRH” or “GHRH 1-44”.
How it works
- Gs-coupled agonist at the pituitary GHRH receptor. GHRH binds a class B G protein-coupled receptor expressed almost exclusively on anterior pituitary somatotrophs, raising intracellular cAMP and driving both growth hormone release and somatotroph proliferation (Mayo, Molecular Endocrinology, 1992;6(10):1734–1744). A single Asp60-to-Gly substitution in this receptor causes the hypoplastic pituitary of the little mouse (Lin et al., Nature, 1993;364(6434):208–213), and a 2.6 Å cryo-EM structure of the human receptor bound to GHRH and the stimulatory G protein mapped the peptide’s N-terminus into its binding pocket (Zhou et al., Nature Communications, 2020;11(1):5205).
- A selective, fast secretagogue gated by somatostatin. In healthy adults a 1 µg/kg intravenous bolus produced prompt growth hormone peaks with no change in prolactin, LH, FSH, TSH or cortisol, and only mild flushing (Gelato et al., Journal of Clinical Endocrinology and Metabolism, 1983;57(3):674–676). Hypothalamic somatostatin sets the ceiling: in six normal men, a maximal 100 µg bolus of GHRH-(1-44) followed by arginine (with TRH) raised peak growth hormone to 72.7 µg/L against 44.9 µg/L for GHRH alone, while arginine had no direct effect on pituitary cells, which is why it is read as a somatostatin suppressor and partners GHRH in the diagnostic test (Alba-Roth et al., Journal of Clinical Endocrinology and Metabolism, 1988;67(6):1186–1189).
- Cleared within minutes by a plasma dipeptidyl peptidase. In human plasma GRH(1-44)-NH2 is cut between Ala2 and Asp3 to GRH(3-44)-NH2, a fragment that is fully immunoreactive but has less than one-thousandth of the biological activity; the intact peptide’s half-life was 17 minutes in vitro and 6.8 minutes after intravenous injection (Frohman et al., Journal of Clinical Investigation, 1986;78(4):906–913). This N-terminal lability is why immunoassays overstate active hormone and why the therapeutic analogs were built to resist that cleavage.
- The N-terminal 29 residues carry the activity. In seven normal subjects an equivalent dose of the amidated 1-29 fragment produced growth hormone responses no different from those of the 1-40 tumor peptide (Grossman et al., British Medical Journal, 1984;288(6433):1785–1787), which made sermorelin the preferred clinical form.
Research status
Diagnostic use defined the clinical record. In 1983, 10 µg/kg of intravenous hpGRF-40 raised growth hormone in all 6 normal men and in 3 of 7 adults with isolated childhood-onset deficiency, suggesting that some patients had hypothalamic rather than pituitary disease (Borges et al., Lancet, 1983;2(8342):119–124). The test that mattered was GHRH combined with arginine. In 40 hypopituitary adults it classified every patient as deficient where insulin-induced hypoglycemia missed several, at a higher cutoff (9 µg/L versus 3 µg/L) because the stimulus is more potent (Aimaretti et al., Journal of Clinical Endocrinology and Metabolism, 1998;83(5):1615–1618). A US multicenter comparison of six tests in 39 patients with multiple pituitary hormone deficiencies and 34 matched controls found the insulin tolerance test and the arginine-plus-GHRH test to be the most accurate, with a 4.1 µg/L cutoff giving 95% sensitivity and 91% specificity for the GHRH combination, which patients preferred (Biller et al., Journal of Clinical Endocrinology and Metabolism, 2002;87(5):2067–2079). Because obesity blunts the response, Italian investigators derived body mass index-specific cutoffs from 322 patients and 318 controls, 11.5 µg/L for lean and 8.0 µg/L for overweight subjects (Corneli et al., European Journal of Endocrinology, 2005;153(2):257–264). The Endocrine Society’s 2011 adult guideline accepted the test with body mass index-dependent cutoffs (Molitch et al., Journal of Clinical Endocrinology and Metabolism, 2011;96(6):1587–1609). Much of this validation used the licensed 1-29 reagent rather than the native peptide.
The test outlived its US reagent. The only GHRH-class diagnostic ever approved in the United States was Geref (sermorelin acetate, NDA 019863), approved December 28, 1990. EMD Serono announced its discontinuation in July 2008, a clinical review recommended the glucagon stimulation test in its place while recombinant GHRH remained unavailable (Yuen et al., Journal of Clinical Endocrinology and Metabolism, 2009;94(8):2702–2707), and the FDA withdrew the Geref approvals effective June 18, 2009. The eventual replacement was not a GHRH. Oral macimorelin, a ghrelin-receptor agonist, was first tested against the arginine-GHRH combination in a 101-participant phase 3 study (NCT00448747, completed July 2011), then validated against the insulin tolerance test with a 5.1 ng/mL cutoff (Garcia et al., Journal of Clinical Endocrinology and Metabolism, 2018;103(8):3083–3093), and Macrilen was approved under NDA 205598 on December 20, 2017; Drugs@FDA now lists its US marketing status as discontinued. Outside the US, somatorelin acetate carries a Japanese Accepted Name and the ATC code V04CD05 for tests of pituitary function, with GRF as its trade name. The 2019 American Association of Clinical Endocrinologists adult guideline was written for a US practice in which the GHRH-arginine test could no longer be performed (Yuen et al., Endocrine Practice, 2019;25(11):1191–1232).
Therapeutic trials of the native peptide were small and never reached approval. Thorner’s group treated two growth hormone-deficient children with 1 to 3 µg/kg of GRF every 3 hours by infusion pump for 6 months: growth velocity rose from 4.6 to 7.1 cm per year in one child and from 2.1 to 13.7 cm per year in the other (Thorner et al., New England Journal of Medicine, 1985;312(1):4–9). That pediatric program was carried forward with the 1-29 fragment and became Geref’s 1997 pediatric approval, not a 1-44 product. In healthy old men, 14-day continuous subcutaneous infusion of GHRH 1-44 raised 24-hour growth hormone, peak number and IGF-I (Corpas et al., Journal of Clinical Endocrinology and Metabolism, 1993;76(1):134–138). Four nighttime 50 µg intravenous boluses in 7 men raised slow-wave sleep from 14.0% to 20.2% of the night and blunted nocturnal cortisol (Steiger et al., Neuroendocrinology, 1992;56(4):566–573). None of these studies progressed to a registered development program for the unmodified peptide.
Later trials registered as “GHRH” used analogs. Theratechnologies stabilized the full 1-44 sequence as tesamorelin; in 412 HIV-infected patients with abdominal fat accumulation, 2 mg daily for 26 weeks cut visceral adipose tissue by 15.2% against a 5.0% increase on placebo (Falutz et al., New England Journal of Medicine, 2007;357(23):2359–2370), and Egrifta was approved under BLA 022505 on November 10, 2010. A Massachusetts General Hospital trial registered as “GHRH1-44” in 60 obese adults (NCT00675506) was in fact a 12-month trial of tesamorelin, which reduced visceral fat by 35 cm² relative to placebo (Makimura et al., Journal of Clinical Endocrinology and Metabolism, 2012;97(12):4769–4779), and a 22-participant University of Texas Medical Branch cognition pilot (NCT02553603) likewise used 1 mg tesamorelin and found no significant change after 10 weeks (Stewart et al., eNeurologicalSci, 2026;44:100616). Small academic GHRH studies in older adults at the University of Pennsylvania (NCT01410799, 13 participants) and Johns Hopkins (NCT00807365, 5 participants) were terminated early. As of November 2026, ClinicalTrials.gov lists no recruiting or active interventional study of the unmodified 1-44 peptide; the recruiting GHRH-class trials are of tesamorelin.
Pathophysiology. Ectopic GHRH secretion by neuroendocrine tumors, mostly of lung or pancreas, is a rare cause of acromegaly: a 2022 review compiled 127 cases reported since 1982, marked by pituitary hyperplasia rather than adenoma and a relatively favorable prognosis after resection (Zendran et al., Frontiers in Endocrinology, 2022;13:867965).
Common dosage forms
- No approved presentation in the United States. No FDA-approved drug or biologic contains the native 44-residue peptide, and no compounded form has an FDA-recognized basis.
- Somatorelin acetate injection (Japan). A physician-administered diagnostic injection under the trade name GRF is the only pharmaceutical presentation of the native sequence documented in a national regulatory record.
- Research-market lyophilized vials. Unregulated lyophilized GHRH 1-44 powder, usually labeled “GHRH” and offered for laboratory use only.
Key considerations
- Regulatory status. The Research Market status reflects the absence of any FDA-approved product containing the native 44-residue peptide and of any registered US development program for it. The only US-approved GHRH-class products have been the 1-29 fragment sermorelin (Geref, approvals withdrawn in 2009) and the stabilized 1-44 analog tesamorelin (Egrifta, approved November 10, 2010), both different molecules.
- Not interchangeable with its analogs. GHRH (1-44), sermorelin, tesamorelin, CJC-1295 and CJC-1295 no DAC share a receptor but differ in sequence, half-life and evidence; the visceral-fat data belong to tesamorelin, the pediatric approval belonged to sermorelin, and the native peptide’s own human data come from small 1980s and 1990s studies.
- A half-life of minutes. Plasma dipeptidyl peptidase inactivates the native peptide with an in vivo half-life of about 7 minutes, so a single injection produces one brief growth hormone pulse; sustained effects required pumps or continuous infusion.
- A diagnostic with a US supply gap. The GHRH-arginine test remains one of the most accurate growth hormone stimulation tests, but no GHRH reagent has been marketed in the United States since 2008, so US practice relies on the insulin tolerance and glucagon tests, with oral macimorelin approved but listed as discontinued.
- Anti-doping. The World Anti-Doping Agency’s 2026 Prohibited List bans growth hormone-releasing hormone and its analogs at all times under section S2.4, naming CJC-1293, CJC-1295, sermorelin and tesamorelin as examples; the native hormone is the named parent of that entry.